Immunovant Gets Positive Data From Graves' Disease Treatment Trial
By Sabela Ojea
Immunovant said it received positive data from its ongoing 24-week Phase 2 clinical trial for its batoclimab treatment for Graves' disease.
The clinical-stage immunology company on Wednesday said the trial results in patients with Graves' disease meaningfully exceeded 50% response rates.
Batoclimab was generally well tolerated with no new safety signals observed in the initial data set.
Graves' disease is an immune system disorder.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
December 20, 2023 17:25 ET (22:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks